{"id":297348,"date":"2026-03-24T00:00:00","date_gmt":"2026-03-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocv0026-2024-biopharma-acute-coronary-syndrome-current-treatment-treatment-algorithms-claims-data\/"},"modified":"2026-04-22T05:09:31","modified_gmt":"2026-04-22T05:09:31","slug":"algocv0026-2026-biopharma-acute-coronary-syndrome-current-treatment-treatment-algorithms-claims-data-analysis-acute","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocv0026-2026-biopharma-acute-coronary-syndrome-current-treatment-treatment-algorithms-claims-data-analysis-acute\/","title":{"rendered":"Acute Coronary Syndrome &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Acute Coronary Syndrome: Secondary Prevention (US)"},"content":{"rendered":"<p class=\"text-align-left\">Acute coronary syndrome (<abbr title=\"acute coronary syndrome\">ACS<\/abbr>) is an umbrella term encompassing myocardial infarction and unstable angina. This report focuses on the secondary prevention of <abbr title=\"acute coronary syndrome\">ACS<\/abbr> (post-<abbr title=\"acute coronary syndrome\">ACS<\/abbr>), aimed at preventing recurrent <abbr title=\"cardiovascular\">CV<\/abbr> events, adverse cardiac remodeling, and prolonging survival. The current post-<abbr title=\"acute coronary syndrome\">ACS<\/abbr> drug market is dominated by generic therapies such as aspirin, statins,\u00a0<abbr title=\"renin-angiotensin-aldosterone system\">RAAS<\/abbr> inhibitors, and beta blockers. Key brands include <abbr title=\"proprotein convertase subtilisin\/kexin type 9\">PCSK9<\/abbr> inhibitors (evolocumab, alirocumab, inclisiran), <abbr title=\"adenosine triphosphate citrate lyase \">ACL<\/abbr> inhibitors (bempedoic acid), P2Y12 inhibitors (ticagrelor), anti-inflammatory agents (low-dose colchicine), and prescription omega-3 fatty acids (icosapent ethyl). In this report, we use patient-level claims data to analyze prescribing dynamics in the U.S. post-<abbr title=\"acute coronary syndrome\">ACS<\/abbr> drug market and provide insights into the factors shaping treatment patterns among newly diagnosed and recently treated patients.<\/p>\n<p class=\"text-align-left\"><strong>Questions answered<\/strong><\/p>\n<ul>\n<li class=\"text-align-left\">What patient shares do key therapies and brands garner by line of therapy in newly diagnosed post-<abbr title=\"acute coronary syndrome\">ACS<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed post-<abbr title=\"acute coronary syndrome\">ACS<\/abbr> patients?<\/li>\n<li class=\"text-align-left\">How have PCKS9 inhibitors and bempedoic acid been integrated into the treatment algorithm, and what is their source of business?<\/li>\n<li class=\"text-align-left\">What percentage of post-<abbr title=\"acute coronary syndrome\">ACS<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly?<\/li>\n<li class=\"text-align-left\">What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li class=\"text-align-left\">What percentage of post-<abbr title=\"acute coronary syndrome\">ACS<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li class=\"text-align-left\">What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p class=\"text-align-left\"><strong>Product description<\/strong><\/p>\n<p class=\"text-align-left\">Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall<span class=\"ice-ins ice-cts-1\" data-changedata=\"\" data-cid=\"3\" data-last-change-time=\"1773300771107\" data-time=\"1773300771107\" data-userid=\"63125\" data-username=\"Megha\">,<\/span> using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p class=\"text-align-left\"><strong>Key drugs covered<\/strong><\/p>\n<p class=\"text-align-left\">Evolocumab, alirocumab, inclisiran,\u00a0bempedoic acid, icosapent ethyl, colchicine\u00a0ticagrelor<\/p>\n<p class=\"text-align-left\"><strong>Key analyses:<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Brand \/ therapy usage across longitudinal patient sample<\/li>\n<li>Newly diagnosed patient analysis<\/li>\n<li>Treatment initiation and progression<\/li>\n<li>Line of therapy analysis<\/li>\n<li>Combination therapy analysis<\/li>\n<li>Source of business for recently treated patients<\/li>\n<li>Persistency and compliance analysis<\/li>\n<li>Product-level patient flow charts<\/li>\n<\/ul>\n<p class=\"text-align-left\"><strong>Product enhancement<\/strong><\/p>\n<p class=\"text-align-left\">Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-297348","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-coronary-syndrome","biopharma-therapy-areas-cardiovascular","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/297348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/297348\/revisions"}],"predecessor-version":[{"id":575173,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/297348\/revisions\/575173"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=297348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}